[논문]Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers

Lee, Jieon; Lee, Howard; Jang, Kyungho; Lim, Kyoung Soo; Shin, Dongseong; Yu, Kyung-Sang

doi:10.2147/DDDT.S68574

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers 원문보기

Drug design, development and therapy, v.8, 2014년, pp.1781 - 1788

Lee, Jieon (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea) , Lee, Howard (Clinical Trials Center, Seoul National University Hospital, Seoul, Republic of Korea) , Jang, Kyungho (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea) , Lim, Kyoung Soo (Department of Clinical Pharmacology and Therapeutics, CHA University School of Medicine and CHA Bundang Medical Center, Seongnam, Republic of Korea) , Shin, Dongseong (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea) , Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea)

Abstract ▼ AI-Helper

PurposeAlthough cilnidipine and valsartan are widely coadministered to patients with hypertension, their drug–drug interaction potential has not been investigated. This study compared the pharmacokinetic (PK), pharmacodynamic (PD), and tolerability profiles of cilnidipine and valsartan, both alone and in combination, in healthy male subjects.Patients and methodsFifty-four subjects, enrolled into an open-label, single-dose, three-treatment, three-period crossover study, randomly received cilnidipine (10 mg), valsartan (160 mg), or both according to one of six sequences. Blood samples were collected at baseline and up to 24 hours after drug administration in each period. Plasma concentrations of cilnidipine and valsartan were determined by liquid chromatography with tandem mass spectrometry. Maximum plasma concentration (Cmax) and area under the concentration-time curve from 0 to the last measurable time (AUClast) were estimated using a noncompartmental method. Tolerability was evaluated by assessing adverse events (AEs), vital signs, electrocardiograms, and clinical laboratory tests. Blood pressure was also measured for PD assessment.ResultsA total of 51 subjects completed the study. The PK profile of cilnidipine was not significantly affected by coadministered valsartan; the geometric mean ratio and 90% confidence interval (90% CI) of AUClast for cilnidipine with and without valsartan was 1.04 (0.98–1.10). Likewise, cilnidipine did not affect the PK of valsartan; the geometric mean ratio (90% CI) of AUClast for valsartan with and without cilnidipine was 0.94 (0.83–1.07). Coadministration of cilnidipine and valsartan reduced blood pressure in an additive way. No serious AEs were reported, and both cilnidipine and valsartan were well tolerated.ConclusionCoadministered cilnidipine and valsartan do not cause a significant PK or PD interaction, and they are well tolerated.

주제어

참고문헌 (24)

1 Chobanian AV Bakris GL Black HR National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report JAMA 2003 289 19 2560 2572 12748199

상세보기
2 Meka N Katragadda S Cherian B Arora RR Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers Am J Ther 2010 17 1 61 67 20090431

상세보기
3 Kim-Mitsuyama S Ogawa H Matsui K Jinnouchi T Jinnouchi H Arakawa K An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone Kidney Int 2013 83 1 167 176 23051740
4 Woo KT Wong KS Choong HL Foo MW Tan HK Chan CM Angiotensin receptor blocker and calcium channel blocker combination prevents cardiovascular events in CKD better than high-dose ARB alone Kidney Int 2013 84 1 214 215 23812366

상세보기
5 Mori H Ukai H Yamamoto H Current status of antihypertensive prescription and associated blood pressure control in Japan Hypertens Res 2006 29 3 143 151 16755149

상세보기
6 Brachmann J Ansari A Mahla G Handrock R Klebs S Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy Adv Ther 2008 25 5 399 411 18465097

상세보기
7 Minami J Kawano Y Makino Y Matsuoka H Takishita S Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension Br J Clin Pharmacol 2000 50 6 615 620 11136301
8 Kario K Nariyama J Kido H Effect of a novel calcium channel blocker on abnormal nocturnal blood pressure in hypertensive patients J Clin Hypertens (Greenwich) 2013 15 7 465 472 23815534
9 Minami J Ishimitsu T Kawano Y Numabe A Matsuoka H Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard J Cardiovasc Pharmacol 1998 32 2 331 336 9700998

상세보기
10 Mistry NB Westheim AS Kjeldsen SE The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials Expert Opin Pharmacother 2006 7 5 575 581 16553573

상세보기
11 Biswas PN Wilton LV Shakir SW The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England J Hum Hypertens 2002 16 11 795 803 12444541

상세보기
12 Williams JR Revising the Declaration of Helsinki World Med J 2008 54 120 122

상세보기
13 Markham A Goa KL Valsartan. A review of its pharmacology and therapeutic use in essential hypertension Drugs 1997 54 2 299 311 9257084
14 Kanaoka T Tamura K Wakui H L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease Int J Mol Sci 2013 14 8 16866 16881 23959116
15 Liu XQ Zhao Y Li D Qian ZY Wang GJ Metabolism and metabolic inhibition of cilnidipine in human liver microsomes Acta Pharmacol Sin 2003 24 3 263 268 12617777
16 Poirier A Cascais AC Funk C Lavé T Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data Chem Biodivers 2009 6 11 1975 1987 19937834

상세보기
17 Julius S Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation Cardiology 1999 91 Suppl 1 S8 S13
18 Csajka C Buclin T Fattinger K Brunner HR Biollaz J Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers Clin Pharmacokinet 2002 41 2 137 152 11888333

상세보기
19 Tanigawara Y Yoshihara K Kuramoto K Arakawa K Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis Drug Metab Pharmacokinet 2009 24 4 376 388 19745564

상세보기
20 Lee J Han S Jeon S Hong T Yim DS Pharmacokinetic-pharmacodynamic model of fimasartan applied to predict the influence of a high fat diet on its blood pressure-lowering effect in healthy subjects Eur J Clin Pharmacol 2013 69 1 11 20 22660441

상세보기
21 Takahara A Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release Cardiovasc Ther 2009 27 2 124 139 19426250
22 Philips B Somer V American Pharmaceutical Association Drug Information Handbook for Cardiology Hudson, OH Lexi-Comp 2000
23 Kondrack R Mohiuddin S Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy Expert Opin Drug Metab Toxicol 2009 5 9 1125 1134 19689218
24 Lee H Kim KS Chae SC Jeong MH Kim DS Oh BH Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension Clin Ther 2013 35 9 1337 1349 23932463

LOADING...

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (24)

이 논문을 인용한 문헌

연구과제 타임라인

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트

연합인증

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (24)

이 논문을 인용한 문헌

연구과제 타임라인

전체(0) 논문(0) 특허(0) 보고서(0)

전체(0) 논문(0) 특허(0) 보고서(0)

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트